News & Updates

Use of a novel drug delivery system (DDS) to deliver a therapeutic compound in the colon has been successful, achieving the intended function with no serious adverse events, reports a study presented at the recent Crohn’s & Colitis Congress (CCC 2023).

Patients with dermatomyositis (DM) who are positive for antimelanoma differentiation-associated gene 5 antibody (anti-MDA5) are more likely to have anti-Ro52 antibodies as well, and such coexistence appears to heighten the risks of rapidly progressive interstitial lung disease (ILD) and mortality, suggests a recent study.

Adherence to gluten-free diet (GFD) in individuals with celiac disease and inflammatory bowel disease (IBD) appears to be low, according to a study.

The addition of blinatumomab to chemotherapy extended overall survival (OS) in adults with measurable residual disease (MRD)-negative B-lineage acute lymphoblastic leukaemia (ALL), according to results of the phase III ECOG-ACRIN E1910 trial.

Ulcerative colitis (UC) flare at 12 months has occurred in more than half of UC patients with tofacitinib dose de-escalation, according to a study presented at the recent Crohn’s & Colitis Congress (CCC 2023). Factors associated with UC flare following de-escalation are shorter induction course (<16 weeks) and active disease at 6 months of tofacitinib.

Use of dexamethasone has no effect on postoperative concentration of cardiac troponin I (TnI) or T (TnT) on the first postoperative morning after total knee arthroplasty (TKA), suggests a recent study.

Participating in an individualized rehabilitation program is beneficial to children with cancer, yielding significant gains in function without any adverse consequences, as reported in a study from Singapore.